NFKB1 and neoplasm: Silibinin’s balanced modulation enhances Nrf2 without hyperactivation and suppresses NF-κB via IκBα stabilization, thereby avoiding these pitfalls, as evidenced by a 50% reduction in tumor size in TNBC xenografts [128,129].